P53 polymorphisms as a potential marker for predisposition for non-Hodgkin malignant lymphomas

Gematologiya i Transfusiologiya

Volumn 55, Issue 1, 2010, Pages 11-17

  Pospelova, T I ^a   Voropaeva, E N ^a   Voevoda, M I ^b   Berezina, O V ^a  

^a NOVOSIBIRSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^b Institute of Therapy   (Russian Federation)

Author keywords

Genetic polymorphism; Liability; Non hodgkin's lymphomas; P53

Indexed keywords

EID: 77952057710     PISSN: 02345730     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Skibola C. F., Curry J. D., Nieters A. Genetic susceptibility to lymphoma. Haematologica 2007; 92: 960-969.
2. Thiagalingam S. A. Cascade of modules of a network defines cancer progression. Cancer Res. 2006; 66(15): 7379-7385.
3. Mitra S., Misra C., Singh R. K. et al. Association of specific genotype and haplotype of p53 gene with cervical cancer in India. J. Clin. Pathol. 2005; 58(1): 26-31.
4. Wilson W. A., Teruya-Feldstein J., Fest T. et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997; 89(2): 601-609.
5. Bellido M., Capello D., Altes A. et al. Bcl-6, p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement. Haematologica 2002; 87(9): 908-917.
6. Scorpa A., Moore P. S., Rigaurd G. et al. Molecular features of primary mediastinal B-cell lymphoma: involvement of P16INK4A, p53 and c-myc. Br. J. Haematol. 1999; 107(1): 106-113.
7. Gaidano G., Volpe G., Pastore C. et al. Detection of BCL-6 rearrangements and p53 mutations in Malt-lymphomas. Am. J. Hematol. 1997; 56(4): 206-213.
8. Sun Y., Keshava C., Sharp D. S. et al. DNA sequence variants of p53. Cancer and aging. Am. J. Hum. Genet. 1999; 65(6): 1779-1782.
9. Bonafe M., Salvioli M., Barbi C. et al. The different apoptotic potential of the p53 codon 72 alleles increases with age and modulates in vivo ischemia-induced cell death. Cell Death Differ. 2004; 11(9): 962-973.
10. Dumont P., Leu J. I., Delia Pietra A. C. 3rd et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 2003; 33(3): 357-365.
11. Sallivan A., Syed N., Gaseo M. et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004; 23(19): 3328-3337.
12. 14. Lazar V., Hazard F., Bertin F. et al. Simple sequence repeat polymorphism within the p53gene. Oncogene 1993; 8:1703-1705. (Pubitemid 23189070)
13. Peller S., Kopilova Y., Slutzki S. et al. A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol. 1995; 14(12): 983-990.
14. Ghosh A., Deborah Stewart D., Matlashewski G. et al. Regulation of human p53 activity and cell localization by alternative splicing. Mol. Cell Biol. 2004; 24(18): 7987-7997.
15. Wu X., Zhao H., Amos C. I. et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J. Natl. Cancer Inst. 2002; 94(9): 681-690.
16. Storey A., Thomas M., Kalita A. et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393: 229-234.
17. Endoh C., Satoh M., Chin E. et al. Aberrations of the p53 gene in roentgenographically occult squamous cell carcinoma of the lung. Kyobu Geka 1996; 49: 990-993.
18. Murata M., Tagawa M., Kimura H. et al. Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients. Int. J. Oncol. 1998; 12(3): 577-581.
19. Huang X. E., Hamajima N., Katsuda N. et al. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 2003; 10(4): 307-311.
20. Wu W., Kakehi Y., Habuchi T. et al. Allelic frequency of p53 gene codon 72 polymorphism in urologie cancers. Jann: Jpn. J. Cancer Res. 1995; 86: 730-736.
21. Bastiaens M. T., Struyk L., Tjong-A-Hung S. P. et al. Cutaneous squamous cell carcinoma and p53 codon 72 polymorphism: a need for screening? Mol. Carcinog. 2001; 30(1): 56-61.
22. Golovleva I., Birgander R., Själander A. et al. Interferon-alpha and p53 alleles involved in nasopharyngeal carcinoma. Carcinogenesis 1997; 18(4): 645-647.
23. Avigad S., Barel D., Blau O. et al. A novel germ line p53 mutation in intron 6 in diverse childhood malignancies. Oncogene 1997; 14(13): 1541-1545.
24. Lehman T. A., Haffty B. G., Carbone C. J. et al. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res. 2000; 60:1062-1069.
25. Lancaster J. M., Brownlee H. A., Wiseman R. W. et al. p53 polymorphism in ovarian and bladder cancer. Lancet 1995; 346(8968): 182.
26. Campbell I. G., Eccles D. M., Dunn B. et al. p53 polymorphism in ovarian and breast cancer. Lancet 1996; 347(8998): 393-394.
27. Mavridou D., Gornall R., Campbell I. G. et al. TP53 intron 6 polymorphism and the risk of ovarian and breast cancer. Br. J. Cancer 1998; 77(4): 676-677.
28. Gemignani F., Moreno V., Landi S. et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of T P53 mRNA. Oncogene 2004; 23(10): 1954-1956.
29. Birgander R., Sjlander A., Rannug A. et al. p53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 1995; 16(9): 2233-2236.
30. Birgander R., Sjlander A., Zhou Z et al. p53 polymorphisms and haplotypes in nasopharyngeal cancer. Hum. Heredity 1996; 46(1): 49-54.
31. Mitra S., Sikdar N., Misra C. et al. Risk assessment of p53 genotypes and haplotypes in tobacco-associated leukoplakia and oral cancer patients from eastern India. Int. J. Cancer 2005; 117(5): 786-793.
32. Tada M., Furuuchi K., Kaneda M. et al. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Cancerogenesis 2001; 22(3): 515-517.
33. Själander A., Birgander R., Athlin L. et al. p53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 1995; 16(7): 1461-1464.
34. Khrunin A. V., Tarskaia L. A., Spitsyn V. A. et al. p53 polymorphisms in Russia and Belarus: correlation of the 2-1-1 haplotype frequency with longitude. Mol. Genet. Genomics 2005; 272(6): 666-672.
35. Brooks L. A., Tidy J. A., Gusterson B. et al. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res. 2000; 60(24): 6875-6877.
36. Anzola M., Cuevas N., Lopez-Martinez M. et al. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett. 2003; 193(2): 199-205.
37. Mabrouk I., Baccouche S., El-Abed R. et al. No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patient. Ann. N. Y. Acad. Sei. 2003; 1010: 764-770.
38. Wang Y. C., Chen C. Y., Wang H. J. et al. Influence of polymorphism at p53, CYPlAl and GSTM1 loci on p53 mutation and association of p53 mutation with prognosis in lung cancer. Zhonghua Yi Xue Za Zhi (Taipei) 1999; 62(7): 402-410.
39. Wang Y., Kringen P., Kristensen G. B. et al. Effect of the codon 72 polymorphism (c.215G -> C, p.Arg72Pro) in combination with somatic sequence variants in the T P53 gene on survival in patients with advanced ovarian carcinoma. Hum. Mutat. 2004; 24(1): 21-34.
40. Hu Y., McDermott M. P., Ahrendt S. A. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin. Cancer Res. 2005; 11(7): 2502-2509.
41. Mechanic L. E., Marrogi A. J., Welsh J. A. et al. Polymorphisms in XPD and 1P53 and mutation in human lung cancer. Carcinogenesis 2005; 26(3): 597-604.
42. Hsieh L. L., Huang T. H., Chen I. H. et al. p53 polymorphisms associated with mutations in and loss of heterozygosity of the p55 gene in male oral squamous cell carcinomas in Taiwan. Br. J. Cancer 2005; 92(1): 30-35.